Theratechnologies Inc (THTX) Stock Price, Quote & News

Company Profile

Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral...

Industry: Biotechnology

Sector: Healthcare

Phone: 514-336-7800

Fax: 514-331-9691

Website: www.theratech.com

Address:

2015 Peel Street, 11th Floor, Montreal, Canada

robanbieber Jun. 17 at 1:42 PM

$THTX what the hell happened in that "independent evaluation" of the offer to buy THTX? now that the price has come from barcoding into a decline the shareholders deserve to know why the company is not being sold to the interested buyers.... if the board cannot answer then time to dump this BOD....

2 · Reply

Annaba514 Jun. 16 at 7:52 PM

$THTX we have to get paul levesque out.. enough is enough.

1 · Reply

jbrown645 Jun. 16 at 6:27 PM

$THTX No Credible source for any 'buyout' possible. Crazy.

0 · Reply

jbrown645 Jun. 16 at 6:06 PM

$THTX This thing moves almost as fast as a slug. Anybody got a CREDIBLE source for a possible buyout?

1 · Reply

JerryL Jun. 16 at 1:51 PM

$THTX daily chart doesn’t look good for the buyout deal

1 · Reply

Annaba514 Jun. 11 at 12:56 PM

$THTX stock of shiit..

0 · Reply

BillBtheBull Jun. 9 at 3:59 AM

$THTX feels about 60/40 there’s no deal and these French Canadian f**ks are just playing games. Sell this pos already

2 · Reply

BirdOnAWire Jun. 6 at 12:51 AM

$THTX I bought this about a month ago for a quick swing because of the buyout rumor. It's been barcoding ever since. Like watching paint dry.

1 · Reply

Joujou29 Jun. 5 at 5:09 PM

$THTX given the time taken, they are propably negotiating the buyout of all american and canadian biotechs at once

0 · Reply

JerryL Jun. 5 at 4:19 PM

$THTX it’s painful to hold this stock, while watching other bio stocks rally

1 · Reply

Theratechnologies Reports on its Annual Meeting of Shareholders

May 2, 2025, 7:30 AM EDT - 6 weeks ago

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV

Apr 18, 2025, 12:01 PM EDT - 2 months ago

Theratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 Offer

Apr 15, 2025, 6:00 PM EDT - 2 months ago

Theratechnologies Provides Update on Sale Process

Apr 12, 2025, 8:46 AM EDT - 2 months ago

Soleus Capital Issues Letter to The Board of Theratechnologies

Apr 11, 2025, 5:00 PM EDT - 2 months ago

Theratechnologies Responds to Future Pak's Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company

Apr 11, 2025, 9:57 AM EDT - 2 months ago

Future Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total Value

Apr 9, 2025, 10:28 AM EDT - 2 months ago

Theratechnologies Inc. (THTX) Q1 2025 Earnings Call Transcript

Apr 9, 2025, 7:30 AM EDT - 2 months ago

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

Apr 3, 2025, 4:30 PM EDT - 2 months ago

Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update

Mar 25, 2025, 5:45 PM EDT - 3 months ago

Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy

Mar 12, 2025, 7:30 AM EDT - 3 months ago

Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI

Mar 12, 2025, 7:30 AM EDT - 3 months ago

Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV

Feb 26, 2025, 1:21 PM EST - 3 months ago

Theratechnologies Inc. (THTX) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 7:30 AM EST - 3 months ago

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024

Feb 14, 2025, 7:30 AM EST - 4 months ago

Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Feb 13, 2025, 7:45 PM EST - 4 months ago

Theratechnologies Resumes Distribution of EGRIFTA SV®

Jan 9, 2025, 5:05 PM EST - 5 months ago

Theratechnologies Provides Update on EGRIFTA SV® Supply

Dec 18, 2024, 1:30 PM EST - 6 months ago

Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment

Dec 10, 2024, 3:15 PM EST - 6 months ago

Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA

Dec 9, 2024, 7:30 AM EST - 6 months ago

Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer

Dec 4, 2024, 7:30 AM EST - 6 months ago

Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada

Dec 3, 2024, 4:30 PM EST - 7 months ago

Theratechnologies Announces Resumed Production of EGRIFTA SV®

Dec 2, 2024, 7:30 AM EST - 7 months ago

Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec

Nov 26, 2024, 7:30 AM EST - 7 months ago

Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review

Oct 17, 2024, 2:00 PM EDT - 8 months ago

Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV

Oct 17, 2024, 7:30 AM EDT - 8 months ago

Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance

Oct 10, 2024, 10:48 AM EDT - 8 months ago

Theratechnologies Inc. (THTX) Q3 2024 Earnings Call Transcript

Oct 10, 2024, 7:30 AM EDT - 8 months ago

Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024

Oct 9, 2024, 7:30 AM EDT - 8 months ago

Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV

Sep 26, 2024, 7:30 AM EDT - 9 months ago

Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update

Sep 17, 2024, 5:00 PM EDT - 9 months ago

Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025

Sep 9, 2024, 7:30 AM EDT - 10 months ago

Theratechnologies to Present at Upcoming Investor Conferences in September

Jul 10, 2024, 10:05 AM EDT - 1 year ago

Theratechnologies Inc. (THTX) Q2 2024 Earnings Call Transcript

Jul 10, 2024, 7:30 AM EDT - 1 year ago

Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024

Jun 26, 2024, 7:30 AM EDT - 1 year ago

Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update

May 23, 2024, 5:00 PM EDT - 1 year ago

Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors

May 2, 2024, 7:30 AM EDT - 1 year ago

Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting

Apr 15, 2024, 4:15 PM EDT - 1 year ago

Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders

Apr 11, 2024, 7:30 AM EDT - 1 year ago

Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Apr 10, 2024, 10:47 AM EDT - 1 year ago

Theratechnologies Inc. (THTX) Q1 2024 Earnings Call Transcript

Apr 10, 2024, 7:30 AM EDT - 1 year ago

Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024

Apr 8, 2024, 4:30 PM EDT - 1 year ago

Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform

Apr 5, 2024, 11:00 AM EDT - 1 year ago

Theratechnologies Appoints Elina Tea to its Board of Directors

Apr 3, 2024, 7:30 AM EDT - 1 year ago

Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update

Mar 28, 2024, 7:30 AM EDT - 1 year ago

Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform

Mar 22, 2024, 9:36 AM EDT - 1 year ago

Theratechnologies Announces Update on its Preclinical Oncology Research Program

Mar 21, 2024, 8:00 PM EDT - 1 year ago

Theratechnologies Appoints Jordan Zwick to its Board of Directors

Mar 21, 2024, 7:30 AM EDT - 1 year ago

Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

Feb 29, 2024, 4:34 PM EST - 1 year ago

Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau

robanbieber Jun. 17 at 1:42 PM

2 · Reply

Annaba514 Jun. 16 at 7:52 PM

$THTX we have to get paul levesque out.. enough is enough.

1 · Reply

jbrown645 Jun. 16 at 6:27 PM

$THTX No Credible source for any 'buyout' possible. Crazy.

0 · Reply

jbrown645 Jun. 16 at 6:06 PM

$THTX This thing moves almost as fast as a slug. Anybody got a CREDIBLE source for a possible buyout?

1 · Reply

JerryL Jun. 16 at 1:51 PM

$THTX daily chart doesn’t look good for the buyout deal

1 · Reply

Annaba514 Jun. 11 at 12:56 PM

$THTX stock of shiit..

0 · Reply

BillBtheBull Jun. 9 at 3:59 AM

$THTX feels about 60/40 there’s no deal and these French Canadian f**ks are just playing games. Sell this pos already

2 · Reply

BirdOnAWire Jun. 6 at 12:51 AM

$THTX I bought this about a month ago for a quick swing because of the buyout rumor. It's been barcoding ever since. Like watching paint dry.

1 · Reply

Joujou29 Jun. 5 at 5:09 PM

$THTX given the time taken, they are propably negotiating the buyout of all american and canadian biotechs at once

0 · Reply

JerryL Jun. 5 at 4:19 PM

$THTX it’s painful to hold this stock, while watching other bio stocks rally

1 · Reply

JerryL Jun. 4 at 3:26 PM

$THTX have a feeling, buyout very soon

0 · Reply

JerryL Jun. 3 at 3:27 PM

$THTX hopefully the buyout price would be $4.

1 · Reply

bobmaga Jun. 3 at 8:41 AM

$THTX When the offer? Almost losing patience...

1 · Reply

Wyckly670 May. 30 at 2:18 PM

$PGEN PDUFA 08/27 - potential breakout with LPS at weekly MA50 + pivot point. Upcoming PDUFA's: $VSTM $KALV $IONS $THTX ...

1 · Reply

KR33P May. 29 at 12:26 PM

$THTX lol i hope these dudes were lying and announce a buyout today st investor meeting

1 · Reply

JerryL May. 27 at 10:19 PM

$THTX company is too slow on the buyout deal. Expect update by the end of this month, but who knows.

0 · Reply

JerryL May. 23 at 6:10 AM

$THTX anyone tried to reach the company to get update?

2 · Reply

DesseinH May. 17 at 6:38 PM

$THTX Its possible that what FuturEPak are seeing, turns them away from the non binding offer they made the way the last interested party also walked? It's been a long time. I'm starting to get worried, if no deal, this essentially crashes.

2 · Reply

JerryL May. 16 at 2:17 PM

$THTX feels this stock is dead

0 · Reply

OMNIFALL May. 14 at 5:15 PM

$THTX when deal?

1 · Reply

TheWolfofMcDonalds May. 12 at 4:56 PM

$THTX Added more 2.50

0 · Reply

JerryL May. 12 at 3:01 PM

$THTX ugly price action means something?

0 · Reply

Market Cap	111.27M
Revenue (ttm)	85.87M
Net Income (ttm)	-8.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-9.68%
Debt to Equity Ratio	-2.02

Volume	135,000
Avg Vol	2,611,460
Day's Range	N/A - N/A
Shares Out	45.98M
Stochastic %K	28%
Beta	0.60
Analysts	Strong Sell
Price Target	$4.96